CARBIOS has signed a multi-year commercial agreement with Indorama Ventures, the world leader in polyester production. CARBIOS will supply recycled monomers that will be transformed into filaments by Indorama Ventures, intended for use in tire reinforcement for Michelin.This new commercial agreement highlights the interest of a new market—industrial fabrics—for high-quality r-PET derived from enzymatic recycling. Clermont-Ferrand (France), 21 July 2025 (17h45 CEST) – CARBIOS (Euronext Growth Paris: ALCRB) ...

Investing in biotechnology stocks is similar to the drug development process itself. That is, investors frequently experience long periods of nothing much happening, interrupted by periods of sharp movement. This is particularly true of small-cap biotech stocks. In many cases, these are unprofitable companies with little to no revenue. However, these are also the companies that can provide the highest return for risk-tolerant investors. The risk with these stocks is that the company can deliver poor clinica ...

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.More information about the firm is available through ...

Key Takeaways VKTX to report Q2 results on July 23 with no revenue expected and a projected EPS loss of $0.44. Investor focus centers on VK2735's VANQUISH trial enrolment and oral dosing study progress. Updates are also expected on IND filing for DACRA obesity candidate and updates on NASH and X-ALD programs.We expect investors to focus on updates related to Viking Therapeutics’ (VKTX) pipeline when it reports second-quarter 2025 results on July 23, after market close. In the last reported quarter, the co ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

MIAMI, July 21, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric, and chronic aging-related conditions, today announced that it Joshua Hare has licensed an issued US patent (12,168,028 B2) for a stem cell technology from the University of Miami. The composition of matter patent protects unique induced pluripotent derived cardiomyogenic cells that have widespread therapeutic ...

有了资金支持，自然为研发提供了极大支撑，技术攻坚成功率也变得更高。 对于科技企业本身而言，赴港上市是新的出海名片。通过H股上市，接触新的国际客户，加速新技术的 推广和新产品的商业化，提升盈利能力的同时，还能吸引优秀的长期国际投资者，进一步提升企业的投 资价值，实现A、H股的价值共振，降低波动风险。 政策加码，为越来越多科技企业解了燃眉之急。科创板"1+6"新政落地，系统性地解决了科技企业融资 难、信息披露风险高等痛点。在金土地上，高科技含量企业更容易生根发芽。 预先审阅制度，彻底解决了个别高科技企业的上市"焦虑症"，硬科技企业上市后备军正加速扩容。 制度包容性不断升级，让一些尚未盈利的硬科技优质企业也有了提前跨进资本市场的可能。生物医药、 人工智能、商业航天等前沿领域的硬科技企业，有机会借助科创板的上市平台，解决融资难的问题。资 本助力之下，它们的科技研发经费更充足，商业化转化来得更快。 7月22日，科创板将迎来开市六周年。从最初的首批25只"星宿股"，到现如今的585只，科创板已发展成 中国硬科技企业最大的资本助力场。 科创板是注册制改革的起点，也是资本市场制度改革的"试验田"。如今，注册制改革已由点及面全 ...

SOPA Images/LightRocket via Getty Images CANADA - 2025/06/08: In this photo illustration, the Sarepta Therapeutics logo is seen displayed on ... More a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) Sarepta Therapeutics has plunged to new lows below $13, down over 35% in recent trading, after rejecting the FDA's request to voluntarily halt all shipments of Elevidys following a third death tied to the gene therapy. Just days after our previous analyses highl ...

Core Insights - Senti Bio is presenting its innovative logic-gated CAR-NK cell therapy, which targets leukemic cells while preserving healthy bone marrow [1] - The presentation will take place at the BioScience Forum on July 23, 2025, featuring Dr. Kanya Rajangam as the speaker [2] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][4] - The company aims to create therapies that can precisely kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing control post-administration [4] - Senti Bio's pipeline includes cell therapies engineered with Gene Circuits targeting both liquid and solid tumors, with preclinical evidence supporting their efficacy in NK and T cells [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1] Group 1: Allegations - The complaint alleges that Sarepta Therapeutics made materially false and misleading statements about ELEVIDYS, a gene therapy for Duchenne muscular dystrophy, which posed significant safety risks to patients [1] - It is claimed that the trial protocols for ELEVIDYS failed to detect severe side effects, leading to potential regulatory scrutiny and halting of recruitment and dosing in trials [1] - The severity of adverse events from ELEVIDYS treatment is said to have misled investors regarding the therapy's approval prospects and overall safety [1] Group 2: Class Action Details - The class period for the lawsuit is defined as June 22, 2023, to June 24, 2025, and shareholders are encouraged to register for participation [2] - The deadline for shareholders to seek lead plaintiff status is August 25, 2025, with no cost or obligation to participate in the case [2] Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3]